Hyperprolactinemia has many causes: pregnancy; prolactinoma; non-functioning pituitary macroadenoma and parasellar tumors, such as meningioma and craniopharyngioma, which compress the stalk or hypothalamus; PRL stimulative drugs, such as dopaminergic antagonists and catecholamine re-uptake inhibitors; hypothyroidism; chest wall diseases; hepatorenal disorders; idiopathic hyperpro¬ lactinemia (1-6).
.
Recently, anti-PRL autoantibody has been detected in sera from some patients with idiopathic hyperpro¬ lactinemia (7, 8) . The Figure 4 shows the changes of serum PRL levels and anti-PRL autoantibody titers in four patients with anti-PRL autoantibody whom we could follow for several years. Hyperprolactinemia persisted during these periods, and patients 3 and 4 became pregnant spontaneously despite the marked hyperprolactinemic state (PRL: 200-300 µg/\). Serum PRL concentrations began to increase during the first trimester and peaked at term with extremely high levels (PRL more than 1000 µg/l); normal lactation started after delivery in both patients. The anti-PRL autoantibody titers were not changed significantly in any of the four patients during these periods, although they were decreased slightly in accordance with the increase in PRL levels during pregnancy in patient 3. The anti-PRL autoantibody titers in the last 3 years showed a tendency to increase. The PRL response to sulpiride or TRH was totally abolished before surgery, while that to sulpiride became normalized despite persisting hyperprolactinemia 13 years after the operation.
Discussion
Anti-PRL autoantibody was detected in hyperpro¬ lactinemic patients at a frequency of 16% in idiopathic hyperprolactinemia, 4 .8% in drug-induced hyperpro¬ lactinemia, 2.7% in prolactinoma and 3.0% in hyperprolactinemia of other causes. The result that the frequency of possession of the anti-PRL autoanti¬ body was significantly higher in idiopathic hyperpro¬ lactinemia than in the other cause-proven hyperprolactinemia suggests that the anti-PRL auto¬ antibody is "another" cause of hyperprolactinemia. This is supported further by the observation that a significant positive correlation existed between the titers of the autoantibody and the serum PRL levels. It is likely that the anti-PRL autoantibody stores endogenous PRL according to the titers. Because the clearance of the autoantibody-bound PRL in the kidney is probably decreased owing to its larger molecular size than free PRL, hyperprolactinemia may occur. In the present study, we confirmed the previous finding (7) that the suppression of PRL levels by dopamine and bromocrip¬ tine was delayed and incomplete in six patients with anti-PRL autoantibody, to support this hypothesis. We observed the anti-PRL autoantibody even in normoprolactinemic subjects, although the frequency and the titers were low. Long-term follow-up is necessary to see if these subjects develop hyperprolactinemia in the future. 
